Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of ₹63,318 Crore up from ₹57,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to ₹56,009 Crore. Consolidated Net Profit of ₹11,142 up 12% from ₹9,958 Crore in the same quarter of the previous year. The Earnings per Share is ₹66.98 in this quarter.
Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%
Related Post
- Nestle India Ltd Q2FY25; 9% rise in Profits
Nestle India Limited is a subsidiary of Nestle which is a Swiss MNC. The company…
-
Navin Fluorine International Ltd Q2FY25; 3% fall in Profits
Navin Fluorine International Ltd is primary engaged in producing refrigeration gases, inorganic fluorides, specialty organofluorines…
-
National Aluminium Company Ltd Q2FY25; 416% rise in Profits
Incorporated in 1981, National Aluminium Company Limited (NALCO) manufactures and sells Alumina and Aluminium Financial…